<b>Alembic in licensing deal with UCB</b><br><br>
Alembic has entered into a licensing agreement with Belgium-based UCB for its drug delivery platform for anti-epileptic drug Keppra XR (Levetiracetam extended release tablets).<br><br>
According to an official release issued by Alembic to the BSE today, under the terms of the agreement, it would receive milestone payments of $11 million and royalty on future
worldwide net sales of Keppra XR.